Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Leukemia

  Free Subscription


Articles published in Exp Hematol

Retrieve available abstracts of 47 articles:
HTML format



Single Articles


    November 2022
  1. GAO X, You X, Droin N, Banaszak LG, et al
    Role of ASXL1 in hematopoiesis and myeloid diseases.
    Exp Hematol. 2022;115:14-19.
    PubMed     Abstract available


    September 2022
  2. DARBANIYAN F, Zheng H, Kanagal-Shamanna R, Lockyer P, et al
    Transcriptomic Signatures of Hypomethylating Agent Failure in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia.
    Exp Hematol. 2022 Sep 20. pii: S0301-472X(22)00697.
    PubMed     Abstract available


  3. PATEL SB, Kuznetsova V, Matkins VR, Franceski AM, et al
    Ex vivo expansion of phenotypic and transcriptomic CML stem cells.
    Exp Hematol. 2022 Sep 14. pii: S0301-472X(22)00696.
    PubMed     Abstract available


  4. THAVAYOGARAJAH T, Sinitski D, Bounkari OE, Torres-Garcia L, et al
    CXCR4 and CD74 together enhance cell survival in response to macrophage migration-inhibitory factor in chronic lymphocytic leukemia.
    Exp Hematol. 2022 Sep 9. pii: S0301-472X(22)00681.
    PubMed     Abstract available


    August 2022
  5. ZHOU C, Uluisik R, Rowley JW, David C, et al
    Germline ETV6 mutation promotes inflammation and disrupts lymphoid development of early hematopoietic progenitors.
    Exp Hematol. 2022;112-113:24-34.
    PubMed     Abstract available


  6. IIDA K, Tsuchiya A, Tamura M, Yamamoto K, et al
    RUNX1 Inhibition Using Lipid Nanoparticle-Mediated Silencing RNA Delivery as an Effective Treatment for Acute Leukemias.
    Exp Hematol. 2022;112-113:1-8.
    PubMed     Abstract available


    July 2022
  7. LIN C, Xu J, Li N, Li Q, et al
    5-Aza-dC promotes T-cell acute lymphoblastic leukemia cell invasion via downregulation of DNMT1 and upregulation of MMP-2 and MMP-9.
    Exp Hematol. 2022 Jul 28. pii: S0301-472X(22)00579.
    PubMed     Abstract available


  8. CAO J, Huang S, Li X
    Rapamycin inhibits the progression of human acute myeloid leukemia by regulating circ_0094100/miR-217/ATP1B1 axis.
    Exp Hematol. 2022 Jul 25. pii: S0301-472X(22)00576.
    PubMed     Abstract available


  9. SOMMERKAMP P, Brown JA, Haltalli MLR, Mercier FE, et al
    m(6)A RNA modifications: Key regulators of normal and malignant hematopoiesis.
    Exp Hematol. 2022;111:25-31.
    PubMed     Abstract available


  10. UPADHYAY P, Beales J, Shah NM, Gruszczynska A, et al
    Recurrent transcriptional responses in AML and MDS patients treated with decitabine.
    Exp Hematol. 2022;111:50-65.
    PubMed     Abstract available


    June 2022
  11. JUNCO JJ, Zorman B, Gant VU Jr, Munoz J, et al
    CRLF2 overexpression results in reduced B-cell differentiation and upregulated E2F signaling in the Dp16 mouse model of Down syndrome.
    Exp Hematol. 2022;110:34-38.
    PubMed     Abstract available


    May 2022
  12. SOOF CM, Spektor TM, Parikh SA, Slager SL, et al
    Serum B-Cell Maturation Antigen is an Independent Prognostic Marker in Previously Untreated Chronic Lymphocytic Leukemia.
    Exp Hematol. 2022 May 4. pii: S0301-472X(22)00205.
    PubMed     Abstract available


  13. KATO H, Maezawa Y, Nishijima D, Iwamoto E, et al
    A high prevalence of myeloid malignancies in progeria with Werner syndrome is associated with p53 insufficiency.
    Exp Hematol. 2022;109:11-17.
    PubMed     Abstract available


    April 2022
  14. PERMATASARI HK, Nakahata S, Ichikawa T, Fauzi YR, et al
    Oncogenic isoform switch of tumor suppressor BCL11B in adult T-cell leukemia/lymphoma.
    Exp Hematol. 2022 Apr 11. pii: S0301-472X(22)00158.
    PubMed     Abstract available


  15. KROPP EM, Li Q
    Mechanisms of Resistance to Targeted Therapies for Relapsed or Refractory Acute Myeloid Leukemia.
    Exp Hematol. 2022 Apr 10. pii: S0301-472X(22)00133.
    PubMed     Abstract available


  16. REDONDO MONTE E, Leubolt G, Windisch R, Kerbs P, et al
    Specific effects of somatic GATA2 zinc finger mutations on erythroid differentiation.
    Exp Hematol. 2022;108:26-35.
    PubMed     Abstract available


  17. KLEMPNAUER KH
    C/EBPbeta sustains the oncogenic program of AML cells by cooperating with MYB and co-activator p300 in a transcriptional module.
    Exp Hematol. 2022;108:8-15.
    PubMed     Abstract available


    March 2022
  18. GERRITSEN M, Hilgendorf S, Yi G, Wierenga ATJ, et al
    Presence of mutant p53 increases stem-cell frequency and is associated with reduced binding to classical TP53 binding sites in cell lines and primary AMLs.
    Exp Hematol. 2022 Mar 18. pii: S0301-472X(22)00128.
    PubMed     Abstract available


  19. SHABASHVILI DE, Feng Y, Kaur P, Venugopal K, et al
    Combination strategies to promote sensitivity to cytarabine-induced replication stress in acute myeloid leukemia with and without DNMT3A mutations.
    Exp Hematol. 2022 Mar 16. pii: S0301-472X(22)00125.
    PubMed     Abstract available


  20. YAN Y, Upadhyaya R, Zhang VW, Berg T, et al
    Epigenetic Maintenance Strategies after Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia.
    Exp Hematol. 2022 Mar 11. pii: S0301-472X(22)00122.
    PubMed     Abstract available


  21. PAREDES R, Doleschall N, Connors K, Geary B, et al
    EVI1 protein interaction dynamics: Targetable for therapeutic intervention?
    Exp Hematol. 2022;107:1-8.
    PubMed     Abstract available


    February 2022
  22. CAN I, Cox MJ, Siegler EL, Kenderian SS, et al
    Challenges of chimeric antigen receptor T-cell therapy in chronic lymphocytic leukemia: lessons learned.
    Exp Hematol. 2022 Feb 10. pii: S0301-472X(22)00069.
    PubMed     Abstract available


  23. SIMONSEN AT, Meggendorfer M, Hansen MH, Nederby L, et al
    Acute myeloid leukemia displaying clonal instability during treatment: implications for measurable residual disease assessments.
    Exp Hematol. 2022 Feb 2. pii: S0301-472X(22)00001.
    PubMed     Abstract available


  24. ALI A, Vaikari VP, Alachkar H
    CD99 in malignant hematopoiesis.
    Exp Hematol. 2022;106:40-46.
    PubMed    


  25. BIGAS A, Rodriguez-Sevilla JJ, Espinosa L, Gallardo F, et al
    Recent advances in T-cell lymphoid neoplasms.
    Exp Hematol. 2022;106:3-18.
    PubMed     Abstract available


    January 2022
  26. KAPADIA B, Shetty AC, Bollino D, Bhandary B, et al
    Translatome changes in acute myeloid leukemia cells post-exposure to pegcrisantaspase and venetoclax.
    Exp Hematol. 2022 Jan 29. pii: S0301-472X(22)00036.
    PubMed     Abstract available


  27. ZHANG J, Liu X, Yin C, Zong S, et al
    hnRNPK/Beclin1 signaling regulates autophagy to promote imatinib resistance in Philadelphia chromosome-positive acute lymphoblastic leukemia cells.
    Exp Hematol. 2022 Jan 14. pii: S0301-472X(22)00032.
    PubMed     Abstract available


  28. LIU F, Zhao Q, Su Y, Lv J, et al
    Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance.
    Exp Hematol. 2022;105:39-49.
    PubMed     Abstract available


    December 2021
  29. THURGOOD LA, Best OG, Rowland A, Lower KM, et al
    Lipid uptake in chronic lymphocytic leukemia.
    Exp Hematol. 2021 Dec 8. pii: S0301-472X(21)00624.
    PubMed     Abstract available


  30. HE X, Zhang Y, Xu Y, Xie L, et al
    Function of the P2X7 receptor in hematopoiesis and leukemogenesis.
    Exp Hematol. 2021;104:40-47.
    PubMed     Abstract available


    November 2021
  31. KENSWIL KJG, Pisterzi P, Feyen J, Ter Borg M, et al
    Immune composition and its association with hematologic recovery after chemotherapeutic injury in acute myeloid leukemia.
    Exp Hematol. 2021 Nov 17. pii: S0301-472X(21)00426.
    PubMed     Abstract available


  32. MA Y, Chen Z, Yu J
    Pseudogenes and their potential functions in hematopoiesis.
    Exp Hematol. 2021;103:24-29.
    PubMed     Abstract available


    September 2021
  33. TREMBLAY CS, Ting SB, McCluskey A, Robinson PJ, et al
    Shutting the gate: targeting endocytosis in acute leukemia.
    Exp Hematol. 2021 Sep 23. pii: S0301-472X(21)00326.
    PubMed    


  34. LIAO W, Eric Kohler M, Fry T, Ernst P, et al
    Corrigendum to : <[Experimental Hematology 2021; 100: 1-11]>.
    Exp Hematol. 2021 Sep 20. pii: S0301-472X(21)00293.
    PubMed    


  35. MARIN-SANCHEZ A, Martinez-Fernandez G, Gomez-Catalan I, Montoya-Morcillo MC, et al
    Efficacy of chemotherapy protocols for hematological malignancies: H-CVAD versus GELA/BURKIMAB/PETHEMA LAL.
    Exp Hematol. 2021;101-102:49-57.
    PubMed     Abstract available


  36. LI Y, Magee JA
    Transcriptional reprogramming in neonatal hematopoietic stem and progenitor cells.
    Exp Hematol. 2021;101-102:25-33.
    PubMed     Abstract available


    August 2021
  37. LEVESQUE JP, Summers KM, Millard SM, Bisht K, et al
    Role of macrophages and phagocytes in orchestrating normal and pathologic hematopoietic niches.
    Exp Hematol. 2021;100:12-31.
    PubMed     Abstract available


    July 2021
  38. HONDA A, Koya J, Yoshimi A, Miyauchi M, et al
    Loss-of-function mutations in BCOR contribute to chemotherapy resistance in acute myeloid leukemia.
    Exp Hematol. 2021 Jul 29. pii: S0301-472X(21)00280.
    PubMed     Abstract available


  39. LIAO W, Kohler ME, Fry T, Ernst P, et al
    Does lineage plasticity enable escape from CAR-T cell therapy? Lessons from MLL-r leukemia.
    Exp Hematol. 2021 Jul 21. pii: S0301-472X(21)00248.
    PubMed     Abstract available


    June 2021
  40. KAEHLER M, Dworschak M, Rodin JP, Ruemenapp J, et al
    ZFP36L1 plays an ambiguous role in the regulation of cell expansion and negatively regulates CDKN1A in chronic myeloid leukemia cells.
    Exp Hematol. 2021 Jun 3. pii: S0301-472X(21)00199.
    PubMed     Abstract available


  41. MACBETH KJ, Chopra VS, Tang L, Zheng B, et al
    Combination of azacitidine and enasidenib enhances leukemic cell differentiation and cooperatively hypomethylates DNA.
    Exp Hematol. 2021;98:47-52.
    PubMed     Abstract available


    May 2021
  42. GRANDITS AM, Wieser R
    Gene expression changes contribute to stemness and therapy resistance of relapsed acute myeloid leukemia: roles of SOCS2, CALCRL, MTSS1, and KDM6A.
    Exp Hematol. 2021 May 21. pii: S0301-472X(21)00195.
    PubMed     Abstract available


  43. YOKOMIZO-NAKANO T, Sashida G
    Two faces of RUNX3 in myeloid transformation.
    Exp Hematol. 2021;97:14-20.
    PubMed     Abstract available


  44. DI GENUA C, Nerlov C
    To bi or not to bi: Acute erythroid leukemias and hematopoietic lineage choice.
    Exp Hematol. 2021;97:6-13.
    PubMed     Abstract available


    February 2021
  45. SWART LE, Heidenreich O
    The RUNX1/RUNX1T1 network: translating insights into therapeutic options.
    Exp Hematol. 2021;94:1-10.
    PubMed     Abstract available


    January 2021
  46. MILONE G, Scire P, Camuglia MG, Triolo A, et al
    LOW CONTENT OF CLONOGENIC PROGENITORS ON DAY+18, IS ASSOCIATED WITH ACUTE GRAFT VERSUS HOST DISEASE AND PREDICT TRANSPLANT RELATED MORTALITY.
    Exp Hematol. 2021 Jan 11. pii: S0301-472X(21)00003.
    PubMed     Abstract available


  47. AREDE L, Pina C
    Buffering noise: KAT2A modular contributions to stabilization of transcription and cell identity in cancer and development.
    Exp Hematol. 2021;93:25-37.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: